Related Experiment Videos
Flow Cytometric Eosin-5'-Maleimide Test is a Sensitive Screen for Hereditary Spherocytosis
Preethi S Chari1, Sujay Prasad1
1Anand Diagnostic Laboratory, 54, Bowring Tower, Bowring Hospital Road, Shivajinagar, Bengaluru, Karnataka 560001 India.
Summary
The eosin-5'-maleimide (EMA) flow cytometry test is a simple and fast method for diagnosing hereditary spherocytosis (HS). It provides a definitive diagnosis, even when other blood test results overlap.
Area of Science:
- Hematology
- Clinical Diagnostics
- Genetics
Background:
- Hereditary spherocytosis (HS) is a heterogeneous hemolytic anemia caused by red blood cell membrane defects.
- Diagnosis typically involves a combination of clinical evaluation and various laboratory tests.
Purpose of the Study:
- To evaluate the efficacy of the eosin-5 extquotesingle-maleimide (EMA)-binding flow cytometry test for diagnosing hereditary spherocytosis.
- To compare the EMA test with the osmotic fragility test in suspected HS cases.
Main Methods:
- The study involved 51 consecutive suspected hereditary spherocytosis cases aged 10 days to 62 years.
- Evaluated the EMA-binding flow cytometry test and compared it with osmotic fragility.
- 4 additional cases suspected on blood smears underwent EMA testing alone.
Main Results:
- The EMA test identified 16 cases of hereditary spherocytosis.
- Hemoglobin levels and reticulocyte counts overlapped between EMA-positive HS cases and EMA-negative patients.
- The EMA test proved crucial for definitive diagnosis despite overlapping results from other tests.
Conclusions:
- The eosin-5 extquotesingle-maleimide (EMA) flow cytometry test is a simple, rapid, and effective method for confirming hereditary spherocytosis.
- This flow cytometry test offers a definitive diagnostic approach for HS, especially when other hematological parameters are inconclusive.